Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

ADC Therapeutics (ADCT) Leases (2019 - 2026)

ADC Therapeutics has reported Leases over the past 8 years, most recently at $1.2 million for Q1 2026.

  • Quarterly results put Leases at $1.2 million for Q1 2026, down 85.42% from a year ago — trailing twelve months through Mar 2026 was $1.2 million (down 85.42% YoY), and the annual figure for FY2025 was $1.3 million, down 84.47%.
  • Leases reached $1.2 million in Q1 2026 per ADCT's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Leases topped out at $11.2 million in Q1 2023 and bottomed at $1.2 million in Q1 2026.
  • Median Leases over the past 5 years was $8.2 million (2025), compared with a mean of $7.1 million.
  • The largest annual shift saw Leases soared 96284.7% in 2022 before it plummeted 85.42% in 2026.
  • Over 5 years, Leases stood at $6.9 million in 2022, then surged by 52.22% to $10.5 million in 2023, then decreased by 20.52% to $8.4 million in 2024, then plummeted by 84.47% to $1.3 million in 2025, then decreased by 7.48% to $1.2 million in 2026.
  • Business Quant data shows Leases for ADCT at $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.